Article
08 Oct 2026
Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing
AUTHORS CONTENT
Article
02 Jul 2026
Janssen Files BPCIA Complaint Against Alvotech Related To Golimumab Biosimilar
Article
05 Jun 2026
ICC Arbitration Rules Effective June 1, 2026: Key Changes And Practical Takeaways For Parties And Counsel
Article
07 May 2026
AbbVie Regulatory Submission And Deal News
Article
08 Oct 2025
Aflibercept BPCIA Multi-District Litigation Updates
Article
21 May 2025
Teva And Alvotech Announce FDA Approval Of Interchangeability For SELARSDI (Ustekinumab-aekn) With STELARA (Ustekinumab)
Article
20 Sep 2024
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year
Article
10 Jul 2024
Fresenius Announces Launch Of Subcutaneous Formulation Of TYENNE (Tocilizumab-aazg) In The United States
Article
10 Jun 2024
Teva And Alvotech Announce Launch Of SIMLANDI (Adalimumab-ryvk) Injection In The U.S.
Article
08 May 2024
Accord BioPharma, Inc. Announces FDA Approval Of HERCESSI (Trastuzumab-strf)
Article
03 Apr 2024
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada
Article
01 Mar 2024
FDA Approves XOLAIR To Treat Children And Adults With One Or More Food Allergies
Article
17 Jan 2024
Issue 43: PTAB Trial Tracker
Article
13 Nov 2023
Fresenius Kabi Launches TYENNE, The First Approved Tocilizumab Biosimilar In The European Union
Article
26 Jun 2023
Coherus To Acquire Surface Oncology
Article
23 May 2023
Biosimilar Clinical Trial Updates
Article
19 Apr 2023
Celltrion Confirms Bioequivalence For CT-P39 Against Xolair In Interim Results Of Phase 3 Study
Article
02 Feb 2023
Celltrion's Anticancer Biosimilar Debuts In Japan
Article
10 Jan 2023
Year In Review: Top Legal Developments Of 2022
Article
25 Nov 2022
Amneal Launches RELEUKO (filgrastim-ayow) In The United States
